Highlights and Quick Summary
- Capex/Depreciation for the quarter ending September 30, 2023 was -0.67 (a 54.6% increase compared to previous quarter)
- Year-over-year quarterly Capex/Depreciation decreased by -49.3%
- Annual Capex/Depreciation for 2022 was -1.34 (a 56.93% increase from previous year)
- Annual Capex/Depreciation for 2021 was -0.85 (a -94.26% decrease from previous year)
- Twelve month Capex/Depreciation ending September 30, 2023 was -0.71 (a -18.92% decrease compared to previous quarter)
- Twelve month trailing Capex/Depreciation decreased by -64.61% year-over-year
Trailing Capex/Depreciation for the last four month:
| 30 Sep '23 | 30 Jun '23 | 31 Mar '23 | 31 Dec '22 |
|---|---|---|---|
| -0.71 | -0.87 | -1.43 | -2.0 |
Visit stockrow.com/PRME
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Capex/Depreciation of Prime Medicine, Inc.
Most recent Capex/Depreciationof PRME including historical data for past 10 years.Interactive Chart of Capex/Depreciation of Prime Medicine, Inc.
Prime Medicine, Inc. Capex/Depreciation for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | -0.67 | -0.43 | -0.51 | – | – |
| 2022 | -1.31 | -1.41 | -9.88 | -3.47 | -1.34 |
| 2021 | – | – | -0.4 | -11.12 | -0.85 |
| 2020 | -14.86 | – | – | – | -14.86 |
Business Profile of Prime Medicine, Inc.
Sector: Healthcare
Industry: Biotechnology